| |
| Issue |
Title |
| |
| No 4 (2024) |
Analysis of the effectiveness of acne drug therapy |
Abstract
PDF (Rus)
|
|
Yu. E. Melnikova, E. K. Trapchevskaya |
| |
| No 4 (2024) |
Potential role of PAR2 inhibitors for treating rheumatoid arthritis |
Abstract
PDF (Rus)
|
|
V. N. Fedorov, M. K. Korsakov, A. L. Khokhlov, A. V. Arshinov, V. P. Vdovichenko, O. V. Leonova, S. Sh. Suleymanov |
| |
| No 2 (2024) |
Trends in clinical pharmacology as represented by international and specialized journals |
Abstract
PDF (Rus)
|
|
A. S. Kolbin, K. S. Radaeva, A. S. Motrinchuk, I. R. Svechkareva |
| |
| No 2 (2024) |
Focus on lomefloxacin: effectiveness and safety |
Abstract
PDF (Rus)
|
|
A. L. Khokhlov, Ju. V. Rybachkova |
| |
| No 1 (2024) |
Efficacy of interleukin-6 inhibitors as a tool for preventive anti-inflammatory therapy for COVID-19 |
Abstract
PDF (Rus)
|
|
S. K. Zyryanov, O. I. Butranova, A. A. Abramova |
| |
| No 3 (2023) |
Pharmacotherapy of glaucoma in terms of evidence-based medicine |
Abstract
PDF (Rus)
|
|
V. N. Fedorov, V. P. Vdovichenko, M. K. Korsakov, V. V. Strakhov, A. A. Popova, A. I. Khokhlov, S. S. Suleymanov |
| |
| No 3 (2023) |
Optimization of pharmacotherapy of COPD patients using EURO FORTA and STOPP/START criteria |
Abstract
PDF (Rus)
|
|
E. A. Orlova |
| |
| No 4 (2021) |
Heart failure as a risk factor of adverse drug reactions. Part 1: potential changes in pharmacokinetics |
Abstract
PDF (Rus)
|
|
A. P. Pereverzev, O. D. Ostroumova |
| |
| No 4 (2021) |
Heart failure as a risk factor of adverse drug reactions. Part 2: potential changes in pharmacokinetics of some drugs |
Abstract
PDF (Rus)
|
|
A. P. Pereverzev, O. D. Ostroumova |
| |
| No 3 (2021) |
Evaluation of adherence of patients with atrial fibrillation to anticoagulant therapy at the outpatient stage of treatment |
Abstract
PDF (Rus)
|
|
A. V. Sokolov, T. E. Lipatova, O. V. Reshetko |
| |
| No 2S (2020) |
Clinical Pharmacology in Health Care, Teaching and Research |
Abstract
PDF (7,3 Mb) (Rus)
|
|
Article Editorial |
| |
| 1 - 11 of 11 Items |
|
